Ebidta Margins

The capacity utilisation for the company currently stands at 57 percent, which is likely to go up to 58-59% for the year, says John Flintham, senior MD & CEO, Amtek Auto.

Sharda Crop may give 30-40% returns in medium term: Emkay

Emkay has recommended to subscribe to Sharda Cropchem IPO as the company is expected to give 30-40% returns in the medium term. "Issue priced at 12-13x P/E (FY14 EPS) is attractively valued", says the report.

Accumulate KEC International; target Rs 68: KRChoksey

KRChoksey is bullish on KEC International and has recommended accumulate rating on the stock with a target price of Rs 68 in its February 04, 2013 research report.

Hold BHEL; target of Rs 230: KRChoksey

KRChoksey has recommended hold rating on Bharat Heavy Electricals (BHEL) with a target of Rs 230, in its February 05, 2013 research report.

ICRA maintains valuation grade of 'C' to Godrej Industries

ICRA equity research has come out with its update note on Godrej Industries, Q3 FY13. The research firm has maintained company's fundamental grading of '4+' indicating "Strong Fundamentals" and valuation grading of 'C' indicating "Fairly Valued" on a relative basis, in its report dated February 07, 2013.

Hold Unichem Laboratories; target Rs 192: Emkay

Emkay Global Financial Services has recommended hold rating on Unichem Laboratories with a target price of Rs 192, in its January 21, 2013 research report.

Buy Gitanjali Gems; target Rs 742: Emkay

Emkay Global Financial Services is bullish on Gitanjali Gems (GGL) and has recommended buy rating on the stock with a target price of Rs 742 in its December 19, 2012 research report.

Buy IRB Infrastructure; target Rs 171: KRChoksey

KRChoksey is bullish on IRB Infrastructure Developers and has recommended buy rating on the stock with a target price of Rs 171 in its October 31, 2012 research report.

Accumulate Havells India; target of Rs 600: Emkay

Emkay Global Financial Services is bullish on Havells India and has recommended accumulate rating on the stock with a target price of Rs 600 in its October 29, 2012 research report.

Buy Nitin Fire Protection; target Rs 91: SKP Securities

SKP Securities is bullish on Nitin Fire Protection Industries (NFPIL) and has recommended buy rating on the stock with a target price of Rs 91 in its October 16, 2012 research report.

Downgrades intensity likely to abate as profit stabilises

CRISIL's rating actions in the first half (H1) of 2012-13 reflect increased pressure on corporate India's credit quality. CRISIL's credit ratio declined to 0.66 in H1 of 2012-13 from 0.91 in H2 of 2011-12, primarily on account of slowdown in economy.

Buy MBL Infra; target of Rs 271: BP Equities

BP Equities is bullish on MBL Infrastructures and has recommended buy rating on the stock with a target price of Rs 271 in its September 12, 2012 research report.

Corporate Q1 revenue growth drops to 6 quarters low: CRISIL

CRISIL has come out with its report on Q1 results of financial year 2012-13. The aggregate corporate revenue growth has dropped to a 6 quarter low and net profit has fallen by 60% Y-o-Y.

GAIL India Q1 PAT seen down 22.9% at Rs 759.5 cr: Emkay

Emkay Global Financial Services has come out with its earnings estimates on GAIL India for Q1FY13. According to the research firm, company's Q1FY13 sales are likely to go up by 23.3% at Rs 10961 crore, Year-on-Year (YoY) basis.

Buy Ambuja Cements; target Rs 205: GEPL Capital

GEPL Capital is bullish on Ambuja Cements and has recommended buy rating on the stock with a target price of Rs 205 in its April 20, 2012 research report.

CRISIL: Market leader to gain significantly, SPA Research

SPA Research has come out with its report on CRISIL. As per the research firm, CRISIL is a market leader and strong player in rating business in India and expects to maintain its dominance on back of its strong network and brand, rich industry experience, large resources at hand and new product launches.

Subscribe to MT Educare IPO for long term: Nirmal Bang

Nirmal Bang has come out with its report on MT Educare IPO. According to the research firm, one can subscribe to the issue with a long term view.

Subscribe to MCX IPO: Emkay

Emkay Global Financial Services has come out with its report on Multi Commodity Exchange of India Ltd (MCX) IPO.

Alembic Pharma Q2 PBT at Rs 45.04 cr

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 24% increase in revenues to Rs 398.05 crores for the quarter ended 30th September 2011, compared to Rs 321.17 crores in the corresponding quarter last year.